Olaf Eickmeier
Overview
Explore the profile of Olaf Eickmeier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
371
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gronau L, Duecker R, Jerkic S, Eickmeier O, Trischler J, Chiocchetti A, et al.
Int J Mol Sci
. 2024 Jul;
25(14).
PMID: 39062931
microRNA (miR)-146a emerges as a promising post-transcriptional regulator in various inflammatory diseases with different roles for the two isoforms miR-146a-5p and miR-146a-3p. The present study aimed to examine the dual...
2.
Gutmann D, Dressler M, Eickmeier O, Herrmann E, Kirwil M, Schubert R, et al.
Cytokine
. 2023 Dec;
173:156452.
PMID: 38039695
Background: Obesity is known to be a pro-inflammatory condition affecting multiple organs. Obesity as a systemic pro-inflammatory state, might be associated with bronchial inflammation in non-smoking adolescents with a BMI ...
3.
Mainz J, Barucha A, Huang P, Bechinger L, Duckstein F, Polte L, et al.
Front Pharmacol
. 2023 Nov;
14:1167407.
PMID: 38026920
Elexacaftor-tezacaftor-ivacaftor (ETI) is a novel, highly effective CFTR modulator combination proven to enhance lung function and body weight in people with cystic fibrosis (pwCF) carrying a F508del mutation. Recently, we...
4.
Sutharsan S, Dillenhoefer S, Welsner M, Stehling F, Brinkmann F, Burkhart M, et al.
Lancet Reg Health Eur
. 2023 Aug;
32:100690.
PMID: 37554663
Background: Treatment with elexacaftor/tezacaftor/ivacaftor (ETI) improves multiple clinical outcomes in people with cystic fibrosis (pwCF) with at least one F508del allele. This study evaluated the real-world impact of ETI on...
5.
Laubach J, Ludwig M, Horn T, Eickmeier O, Smaczny C, Schubert R, et al.
Front Biosci (Landmark Ed)
. 2023 Aug;
28(7):138.
PMID: 37525914
Background: High TGFβ1-producing variants cause severe clinical disease in F508del homozygous patients. Lately, we showed that a single nucleotide polymorphism (SNP), rs41266431, in the GJA4 gene modifies the disease severity...
6.
Mainz J, Zagoya C, Polte L, Naehrlich L, Sasse L, Eickmeier O, et al.
Front Pharmacol
. 2023 May;
14:1207356.
PMID: 37205908
[This corrects the article DOI: 10.3389/fphar.2022.877118.].
7.
Meoli A, Eickmeier O, Pisi G, Fainardi V, Zielen S, Esposito S
Int J Mol Sci
. 2022 Oct;
23(20).
PMID: 36293274
Cystic fibrosis (CF), the most common genetically inherited disease in Caucasian populations, is a multi-systemic life-threatening autosomal recessive disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator ()...
8.
Wetzstein N, Diricks M, Kohl T, Wichelhaus T, Andres S, Paulowski L, et al.
Microbiol Spectr
. 2022 Aug;
10(4):e0171422.
PMID: 35938728
Infections due to Mycobacterium abscessus are a major cause of mortality and morbidity in cystic fibrosis (CF) patients. Furthermore, M. abscessus has been suspected to be involved in person-to-person transmissions....
9.
Laubach J, Ludwig M, Horn T, Eickmeier O, Smaczny C, Schubert R, et al.
Front Biosci (Landmark Ed)
. 2022 Jun;
27(6):168.
PMID: 35748244
Background: Recently, we provided evidence that a single nucleotide polymorphism (SNP), rs41266431, on the gap junction protein alpha 4 (GJA4) gene, acts as a modifier for clinical disease severity in...
10.
Mainz J, Zagoya C, Polte L, Naehrlich L, Sasse L, Eickmeier O, et al.
Front Pharmacol
. 2022 Jun;
13:877118.
PMID: 35721187
The novel and highly effective CFTR modulator combination of elexacaftor-tezacaftor-ivacaftor (ETI) has been shown to improve lung function and body weight in people with Cystic Fibrosis (pwCF) carrying a F508del...